Regenerative Medical Technology (RMTG) Total Current Liabilities (2017 - 2026)
Regenerative Medical Technology (RMTG) posted quarterly Total Current Liabilities of $38.2 million for Q1 2026, up 27.88% year-over-year from $29.9 million in Q1 2025, and up 3.75% quarter-over-quarter from $36.8 million in Q4 2025.
Regenerative Medical Technology (RMTG) Total Current Liabilities (2017 - 2026) Analysis & Trends
Regenerative Medical Technology's Total Current Liabilities history runs 10 years deep, the most recent figure standing at $38.2 million for Q1 2026.
- In Q1 2026, Total Current Liabilities rose 27.88% year-over-year to $38.2 million; the TTM figure through Mar 2026 stood at $38.2 million (up 27.88% YoY), while the FY2025 annual figure was $36.8 million, up 27.13% from the prior year.
- Total Current Liabilities for Q1 2026 stood at $38.2 million, up from $36.8 million in the prior quarter.
- The five-year high for Total Current Liabilities was $38.2 million in Q1 2026, with the low at $4.8 million in Q1 2022.
- The 5-year median for Total Current Liabilities is $24.4 million (2024), against an average of $21.3 million.
- Peak annual rise in Total Current Liabilities reached 363.0% in 2022, while the deepest fall reached 41.26% in 2022.
- Regenerative Medical Technology's Total Current Liabilities stood at $12.0 million in 2022, then surged by 85.42% to $22.2 million in 2023, then surged by 30.19% to $29.0 million in 2024, then grew by 27.13% to $36.8 million in 2025, then grew by 3.75% to $38.2 million in 2026.
- Business Quant data shows RMTG's Total Current Liabilities at $38.2 million in Q1 2026, $36.8 million in Q4 2025, and $17.3 million in Q3 2025.
Powered by 
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Total Current Liabilities (Qtr) |
|---|---|---|---|---|---|
| 1 | Vertex Pharmaceuticals | 137.11 Bn | 129.26 Bn | 2.84 Bn | 3.94 Bn |
| 2 | Regeneron Pharmaceuticals | 84.98 Bn | 76.99 Bn | 3.93 Bn | 5.53 Bn |
| 3 | Argenx Se | 64.52 Bn | 59.33 Bn | 1.37 Bn | 1.58 Bn |
| 4 | Moderna | 53.23 Bn | 48.09 Bn | 52.00 Mn | 2.53 Bn |
| 5 | BeOne Medicines | 41.23 Bn | 36.14 Bn | 1.53 Bn | 2.12 Bn |
| 6 | Alnylam Pharmaceuticals | 30.65 Bn | 27.34 Bn | 992.69 Mn | 1.51 Bn |
| 7 | Insmed | 27.15 Bn | 25.99 Bn | 358.27 Mn | 438.74 Mn |
| 8 | Royalty Pharma | 26.98 Bn | 26.14 Bn | - | 630.93 Mn |
| 9 | BioNTech SE | 26.78 Bn | 8.39 Bn | 668.28 Mn | 2.49 Bn |
| 10 | Regenerative Medical Technology | 961,772.49 | -99,675.51 | 1.77 Mn | 38.20 Mn |
Historic Data
Download Data| Date | Value |
|---|---|
| Mar 31, 2026 | 38.20 Mn |
| Dec 31, 2025 | 36.82 Mn |
| Sep 30, 2025 | 17.27 Mn |
| Jun 30, 2025 | 30.54 Mn |
| Mar 31, 2025 | 29.88 Mn |
| Dec 31, 2024 | 28.97 Mn |
| Sep 30, 2024 | 27.49 Mn |
| Jun 30, 2024 | 26.42 Mn |
| Mar 31, 2024 | 24.36 Mn |
| Dec 31, 2023 | 22.25 Mn |
| Sep 30, 2023 | 24.43 Mn |
| Jun 30, 2023 | 13.69 Mn |
| Mar 31, 2023 | 12.93 Mn |
| Dec 31, 2022 | 12.00 Mn |
| Sep 30, 2022 | 6.08 Mn |
| Jun 30, 2022 | 5.30 Mn |
| Mar 31, 2022 | 4.82 Mn |
| Dec 31, 2021 | 4.22 Mn |
| Sep 30, 2021 | 10.35 Mn |
| Jun 30, 2021 | 1.14 Mn |